We have examined the clinical efficacy of Qizhi Yifei granules on patients with high peripheral blood eosinophil-type acute exacerbation of chronic obstructive pulmonary disease and its effect on serum interleukin-8, interleukin-17, and tumor necrosis factor-alpha levels. A total of 80 patients were enrolled and assigned to the control p (n = 36) and treatment groups (n = 44) . Patients in the control group received conventional symptomatic treatment, while patients in the treatment group received additional Qizhi Yifei granules based on treatment for the control group. Treatment with Qizhi Yifei granules resulted in early diminution of clinical symptoms; higher acidity levels; lower levels of interleukin-8, interleukin-17, and tumor necrosis factor-alpha; and lower eosinophil count. In addition, the treatment group showed a lower score on disease assessment and higher clinical efficacy than the control group. The incidence of adverse reactions after intervention was not greatly different between the two groups. In conclusion, for patients with high peripheral blood eosinophil-type acute exacerbation of chronic obstructive pulmonary disease, treatment with Qizhi Yifei granules can lower their eosinophil count, alleviate clinical symptoms, and lower inflammatory factors, thus delivering higher clinical efficacy.